Researchers designed a focal adhesion kinase (FAK) inhibitor (compound 7g) that demonstrated antiproliferative activity in KRAS-mutant HCT116 colorectal cancer cells and showed 66.5% tumor growth inhibition in mouse models. (Bioorg Chem)
New FAK inhibitor shows promise in KRAS-mutant colorectal cancer
The CRC Digest